Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells

Abstract Abstract Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is well-recognized for its therapeutic benefits in type 2 diabetes (T2D) and cardiovascular diseases. In this comprehensive in vitro study, we investigated DAPA’s effects on cardiomyocytes, aortic endothelial...

Полное описание

Библиографические подробности

Главные авторы:	Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, Ahmed M. Al-Rawi, Tiana Salomon, Mahra K. Almansoori, Moustafa M. Madkour, Ahmed Mohamed Hamam, Mahmoud M. Ramadan, Quinn P. Peterson, Mohamed A. Saleh
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2024-10-01
Серии:	Cardiovascular Diabetology
Предметы:	Dapagliflozin Sodium-glucose cotransporter Cardiomyocyte Inflammation AKT signaling Endothelial cells
Online-ссылка:	https://doi.org/10.1186/s12933-024-02481-y
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!